Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Blood lead level is a positive predictor of uremic pruritus in patients undergoing hemodialysis

Authors Weng CH, Hsu CW, Hu CC, Yen TH, Chan MJ, Huang WH

Received 23 February 2017

Accepted for publication 3 May 2017

Published 12 June 2017 Volume 2017:13 Pages 717—723

DOI https://doi.org/10.2147/TCRM.S135470

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Deyun Wang

Cheng-Hao Weng,1,2 Ching-Wei Hsu,1,2 Ching-Chih Hu,2,3 Tzung-Hai Yen,1,2 Ming-Jen Chan,1,2 Wen-Hung Huang1,2

1Department of Nephrology and Division of Clinical Toxicology, Chang Gung Memorial Hospital, Linkou Medical Center, 2Department of Medicine, Chang Gung University College of Medicine, Taoyuan, 3Department of Hepatogastroenterology and Liver Research Unit, Chang Gung Memorial Hospital, Keelung, Taiwan

Abstract: Although uremic pruritus (UP) is a common and annoying symptom for end-stage renal disease patients on hemodialysis (HD) and peritoneal dialysis, its pathogenesis is poorly understood. However, systemic inflammation is one of the possible pathogenesis of UP, and blood lead level (BLL) has been noted to be associated with inflammation and nutritional status in long-term HD patients. There might be an interaction or association, therefore, between BLL and UP through systemic inflammation. We analyzed cross-sectional data among 866 participants. All of the 866 patients in this study were stratified into groups with low-normal (<10 µg/dL), high-normal (10–20 µg/dL), and abnormal BLLs (>20 µg/dL). The associations between UP and BLL and the clinical data were analyzed. Multivariate logistic regression demonstrated that HD duration, non-anuria, log ferritin, serum low-density lipoprotein, log BLL, high-normal BLL, and high BLL were associated with UP. In conclusion, BLL was positively associated with UP.

Keywords: blood lead levels, uremic pruritus, hemodialysis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]